Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HRAS G12S

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FGF19 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF3 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF4 amplification + HRAS Q61R + TP53 672+2T>G (6)

HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)

HRAS overexpression + PIK3CA amplification (1)

HRAS overexpression + PIK3CA mutation (1)

FGF19 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF3 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF4 amplification + HRAS Q61R + TP53 672+2T>G (6)

HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)

HRAS overexpression + PIK3CA amplification (1)

HRAS overexpression + PIK3CA mutation (1)

›

HRAS G12S	Urothelial Cancer	HRAS G12S	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12S	Squamous Cell Carcinoma of Head and Neck	HRAS G12S	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS G12S	Solid Tumor	HRAS G12S	Solid Tumor	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D